Amivantamab Plus Lazertinib in Atypical EGFR -Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2
Lists
Only you see this
Abstract
In participants with atypical <i>EGFR</i>-mutated advanced NSCLC, amivantamab-lazertinib demonstrated clinically meaningful antitumor activity with no new safety signals.
BibTeX
@article{tomasini2025amivantamab,
author = {Pascale Tomasini and Yongsheng Wang and Yongsheng Li and Jiuwei Cui and Benjamin Besse and Kōichi Goto and Christina S. Baik and Yiping Zhang and Jong‐Seok Lee and Se‐Hoon Lee and Sebastian Michels and Zacharias Anastasiou and Joshua C. Curtin and Xuesong Lyu and James Mahoney and Levon Demirdjian and Craig S. Meyer and Youyi Zhang and Isabelle Leconte and Patricia Lorenzini and Roland E. Knoblauch and Leonardo Trani and Mahadi Baig and Joshua Bauml and Byoung Chul Cho and Gee‐Chen Chang and Sophie Cousin and Jiuwei Cui and Giuseppe Curigliano and Gianluca Del Conte and Xiaorong Dong and Enriqueta Felip and Pilar Garrido and Nicolas Girard and Adriano Gravina and Frank Griesinger and Matthew A. Gubens and Eric B. Haura and Eiki Ichihara and Dong-Wan Kim and Se Hyun Kim and Yongsheng Li and Shun Lu and Melina E. Marmarelis and Joel W. Neal and Jorge J. Nieva and Luis Paz‐Ares and Niels Reinmuth and Yuki Sato and Alexander I. Spira and Meili Sun and Pascale Tomasini and Marcel Wiesweg and Lin Wu and James Chih‐Hsin Yang and Yu Yao and Yiping Zhang and Minglei Zhuo and Yuki Sato and Alexander Spira and Meili Sun and Pascale Tomasini and Yongsheng Wang and Marcel Wiesweg and Lin Wu and James Chih-Hsin Yang and Yu Yao and Yiping Zhang and Minglei Zhuo},
title = {{Amivantamab Plus Lazertinib in Atypical <i>EGFR</i> -Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2}},
journal = {Journal of Clinical Oncology},
year = {2025},
doi = {10.1200/jco-24-02835},
}